Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.
There's a chance of a severe storm every winter that threatens to knock out the power, block the roads, and even trap residents in their home.
Defining the Antitumor Mechanism of Action of a Clinical-stage Compound as a Selective Degrader of the Nuclear Pore Complex Open Access Linjie Yuan; Wenzhi Ji; Brendan G. Dwyer; Joey Lu; Jing Bian; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results